S1,

Phase 3Small molecule

S1, is one of 230 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

229

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Gastric CancerActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Gastric CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

S1,

CChinese Academy of Medical Sciences

Phase 3

1 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Vidaza

1 8

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

3 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

2 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Colorectal Cancer

NCT05720559

Q3 2027

Phase 2Not yet recruiting

Gastric Cancer

NCT05524974

Phase 2Recruiting

Chemoradiation

NCT07038629

Q4 2027

Phase 2Active, not recruiting

Study completion

NCT05026905

Q3 2028

Phase 2Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06447636

Clinical

Trials by Indication[1]

Gastric Cancer17 trials

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

Unknown status·—·Phase 2·NCT04367025·70 enrolled

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled

Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 1/2·NCT03427684·18 enrolled

Show 14 more trials

Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04250948·108 enrolled

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Active, not recruiting·QQilu Hospital of Shandong University·Phase 2·NCT05586061·55 enrolled

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

Recruiting·RRenJi Hospital·Phase 2·NCT05769725·70 enrolled

SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 1/2·NCT01542294·71 enrolled

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Unknown status·ZZhou Fuxiang·Phase 2·NCT04781686·35 enrolled

The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT01531452·43 enrolled

Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer

Unknown status·JJinling Hospital, China·Phase 2·NCT02949258·40 enrolled

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

Unknown status·SShanghai Zhongshan Hospital··NCT03001726·228 enrolled

Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer

Unknown status·TTianshu Liu·Phase 2·NCT02623153·200 enrolled

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Completed·FFujian Medical University·Phase 2·NCT04195828·106 enrolled

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Not yet recruiting·FFujian Medical University·Phase 2·NCT05524974·203 enrolled

Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT05228743·180 enrolled

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Completed·QQilu Hospital of Shandong University·Phase 2·NCT03878472·25 enrolled

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Unknown status·—·Phase 2·NCT03990103·66 enrolled

Pancreatic Cancer5 trials

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT03403101·65 enrolled

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Terminated·ZZhejiang Provincial People's Hospital·Phase 2·NCT03585062·40 enrolled

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Unknown status·FFudan University·Phase 2·NCT05138159·10 enrolled

Show 2 more trials

Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer

Unknown status·PPeking University·Phase 2·NCT03636308·40 enrolled

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer

Completed·—·Phase 1/2·NCT01781520·47 enrolled

Adenocarcinoma3 trials

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Withdrawn·PPeking University·Phase 2·NCT04863430

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Not yet recruiting·YYu jiren·Phase 2·NCT05970627·30 enrolled

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting·YYu jiren·Phase 2·NCT05729646·90 enrolled

Gastric Adenocarcinoma2 trials

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Unknown status·LLiangjun Zhu M.M.·Phase 2·NCT05237349·38 enrolled

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Recruiting·YYu jiren·Phase 2·NCT05872685·314 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·FFudan University·Phase 2·NCT06447636·20 enrolled

11 more indications

Intraperitoneal1 trial

Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT03061058·240 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Not yet recruiting·NNational Cancer Center Hospital East·Phase 3·NCT04465968·84 enrolled

Esophageal Cancer1 trial

Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial

Unknown status·CChinese Academy of Medical Sciences·Phase 3·NCT02319187·240 enrolled

Non-Small Cell Lung Cancer1 trial

Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection

Unknown status·HHebei Medical University Fourth Hospital·Phase 2·NCT02223611·100 enrolled

Liver Metastases1 trial

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05774964·100 enrolled

Advanced Biliary Tract Carcinoma1 trial

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05822453·20 enrolled

Head and Neck Cancer1 trial

The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

Unknown status·—·Phase 2·NCT02943252·30 enrolled

Chemoradiation1 trial

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07038629·52 enrolled

Colorectal Cancer1 trial

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Not yet recruiting·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05720559·100 enrolled

Chemotherapy1 trial

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT04819971·67 enrolled

Unspecified1 trial

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Active, not recruiting·NNational Health Research Institutes, Taiwan·Phase 2·NCT05026905·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 39 trial records for S1,. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S1, compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S1,. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChinese Academy of Medical Sciences

S1,

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Gastric Cancer17 trials

Pancreatic Cancer5 trials

Adenocarcinoma3 trials

Gastric Adenocarcinoma2 trials

Gastroesophageal Junction Adenocarcinoma1 trial

Intraperitoneal1 trial

Efficacy and Safety1 trial

Esophageal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Liver Metastases1 trial

Advanced Biliary Tract Carcinoma1 trial

Head and Neck Cancer1 trial

Chemoradiation1 trial

Colorectal Cancer1 trial

Chemotherapy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News